Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Dianthus Therapeutics, Inc. (DNTH : NSDQ)

• Company Description    Dianthus Therapeutics Inc. is a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics. Dianthus Therapeutics Inc., formerly known as Magenta Therapeutics Inc., is based in CAMBRIDGE, Mass. Number of Employees: 78

• Price / Volume Information    Yesterday's Closing Price: $37.16 Daily Weekly Monthly 20 Day Moving Average: 912,657 shares Shares Outstanding: 32.19 (millions) Market Capitalization: $1,196.11 (millions) Beta: 1.46 52 Week High: $38.59 52 Week Low: $13.37 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 83.51% 80.28% 12 Week 113.07% 93.55% Year To Date 70.46% 55.06%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7 Times Square 43rd Floor - New York,NY 10036 USA ph: 929-999-4055 fax: - ir@dianthustx.com http://www.dianthustx.com

• General Corporate Information    Officers Marino Garcia - President; Chief Executive Officer and Director Alison F. Lawton - Chairman Ryan Savitz - Chief Financial Officer and Chief Business Officer Edward Carr - Chief Accounting Officer Sujay Kango - Director Peer Information Dianthus Therapeutics, Inc. (CORR.) Dianthus Therapeutics, Inc. (RSPI) Dianthus Therapeutics, Inc. (CGXP) Dianthus Therapeutics, Inc. (BGEN) Dianthus Therapeutics, Inc. (GTBP) Dianthus Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 252828108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/06/25 Share - Related Items Shares Outstanding: 32.19 Most Recent Split Date: 9.00 (0.06:1) Beta: 1.46 Market Capitalization: $1,196.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.88 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.43 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.94 Price/Cash Flow: - Price / Sales: 246.47 EPS Growth vs. Year Ago Period: -72.55% vs. Previous Quarter: -7.32% Sales Growth vs. Year Ago Period: -89.64% vs. Previous Quarter: -83.40% ROE 06/30/25 - -34.72 03/31/25 - -29.26 12/31/24 - -23.91 ROA 06/30/25 - -32.72 03/31/25 - -27.87 12/31/24 - -22.97 Current Ratio 06/30/25 - 13.12 03/31/25 - 15.98 12/31/24 - 15.22 Quick Ratio 06/30/25 - 13.12 03/31/25 - 15.99 12/31/24 - 15.22 Operating Margin 06/30/25 - -2,364.56 03/31/25 - -1,544.23 12/31/24 - -1,362.96 Net Margin 06/30/25 - -2,364.56 03/31/25 - -1,544.23 12/31/24 - -1,362.96 Pre-Tax Margin 06/30/25 - -2,364.60 03/31/25 - -1,544.26 12/31/24 - -1,362.78 Book Value 06/30/25 - 9.42 03/31/25 - 10.23 12/31/24 - 11.91 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©